Previous radiotherapy to % or more of the bone marrow and/or radiation therapy within days prior to study entry Prior radiation therapy is allowed to < % of the bone marrow, but is not permitted within days prior to study registration Concurrent malignancy requiring active therapy\r\n* Patients with localized prostate cancer having undergone surgery or radiation (field confined to =< % of marrow-bearing bone) at least days prior to study treatment are eligible Patients who have received radiation to more than % of marrow-bearing areas No prior radiation to > % of the marrow. Prior radiotherapy within weeks of the first dose of study treatment; patients who have received radiation to more than % of the bone marrow are not eligible at any time Patients must not have received any prior chemotherapy, radiation therapy, immunotherapy or bone marrow transplant for the treatment of DIPG; prior dexamethasone and/or surgery are allowed Participants who have received prior radiation therapy to > % of the bone marrow. The patient has received radiation to ? % of his or her bone marrow within weeks of the first dose of study drug. Prior treatment with radiation therapy involving >=% of the hematopoietically active bone marrow within months before the first dose of study drug. Patients must not have had radiotherapy encompassing > % of the bone marrow within weeks; or any radiation therapy within week prior to day of protocol therapy If the patient received previous radiation therapy, the total absorbed radiation dose at the bone marrow level must be ? Gy Radiation therapy to >% of bone marrow prior to study entry; Prior radiation therapy for treatment of cancer is allowed to <% of the bone marrow. Radiation therapy to more than % of the bone marrow; whole pelvic radiation is considered to be over % Patients who have received either immunotherapy within =< weeks; chemotherapy within =< weeks; or radiation therapy to > % of marrow-bearing bone within =< weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies Radiation therapy to more than % of the bone marrow; whole pelvic radiation is considered to be over % Prior pelvic radiation therapy or patients who have undergone prior radiation to greater than or equal to % of the bone marrow within the past year are excluded; patients who received radiation for prostate cancer are also excluded Subjects who have received radiation therapy targeting > % of the bone marrow space must have completed this at least weeks prior to starting therapy with DSb History of radiation therapy to >= % of the bone marrow for other diseases Having received immunotherapy or chemotherapy within weeks; or radiation therapy to > % of marrow-bearing bone within =< weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies Radiation therapy to more than % of the bone marrow Radiation therapy to more than % of the bone marrow; whole pelvic radiation is considered to be over % Subjects who have received radiation therapy targeting > % of the bone marrow space must have completed this at least weeks prior to starting therapy with AMG- + KRd Prior radiation therapy irradiating more than % of total bone marrow Participants may not have had radiation to > % of the bone marrow Prior abdominal or pelvic radiation therapy or radiation therapy to > % of the bone\n marrow at any time in the past or prior radiation therapy within the past years to\n the breast/sternum, dermal lesions, head or neck. weeks if other bone marrow radiation has been administered. No history of radiation therapy to >= % of the bone marrow for other diseases or history of anthracycline therapy Prior radiation therapy encompassing > % of bone marrow Patients cannot have evidence of immunosuppression or have been treated with immunosuppressive therapy, such as chemotherapy, chronic treatment dose corticosteroids (greater than the equivalent of mg prednisone per day), or radiation therapy to > % of the bone marrow, within months of the first vaccination; treatment or salvage radiation therapy encompassing =< % of bone marrow must have been completed weeks prior to the first vaccination Radiation therapy to more than % of the bone marrow; whole pelvic radiation is considered to be over % Participant has received irradiation to a major bone marrow area as defined as > % of bone marrow (such as, pelvic or abdominal radiation) within days prior to randomization Patients who have received chemotherapy or radiation therapy to > % of marrow bearing bone within < weeks or experimental agent/therapy within weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies Radiation therapy (other than palliative) =< weeks prior to randomization; note: patients who have had > % of their functional bone marrow irradiated are not eligible for this trial Has received prior radiation to > % of the bone marrow Patient must not have had radiation therapy to more than % of the bone marrow; whole pelvic radiation is considered to be over % Radiation therapy to more than % of the bone marrow; whole pelvic radiation is considered to be over %; (ongoing small field radiation therapy for palliation only is allowed) Patients who have received either immunotherapy within =< weeks; chemotherapy within =< weeks; or radiation therapy to > % of marrow-bearing bone within =< weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies Patients who have received chemotherapy within % of marrow-bearing bone within weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies. Patients who have received radiation to more than % of marrow-bearing areas Radiation therapy to greater than % of the bone marrow Radiation therapy to more than % of the bone marrow (note: whole pelvic radiation is considered to be over %) prior radiation therapy with volume of bone marrow treated over %. Radiation therapy to more than % of the bone marrow; whole pelvic radiation is considered to be over % Patients who have received either immunotherapy within =< weeks; chemotherapy within =< weeks; or radiation therapy to > % of marrow-bearing bone within =< weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies Prior radiation therapy allowed to < % of the bone marrow Prior treatment with radiation therapy involving ? % of the hematopoietically active bone marrow within days before the first dose of study drug. Prior treatment with radiation therapy involving >= percent (%) of hematopoietically active bone marrow. Focal radiation therapy within days prior to randomization; radiation therapy to an extended field involving a significant volume of bone marrow within days prior to randomization (i.e., prior radiation must have been to less than % of the bone marrow) Prior treatment with radiation therapy involving ? % of the hematopoietically active bone marrow Radiation therapy to more than % of the bone marrow; whole pelvic radiation is considered to be over % Radiation therapy to % of bone marrow within weeks of first dose Patients who have received either immunotherapy within =< weeks; chemotherapy within =< weeks; or radiation therapy to > % of marrow-bearing bone within =< weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies Focal radiation therapy within days prior to randomization. Radiation therapy to an extended field involving a significant volume of bone marrow within days prior to randomization (i.e., prior radiation must have been to less than % of the bone marrow). Patients must have had at least prior systemic chemotherapy (not just steroids or local radiation); last chemotherapy or radiation must be at least weeks prior to enrollment on this study; patients who decline other potentially curative therapy may be eligible; prior radiation therapy must not have been to more than % of the bone marrow; whole pelvic radiation is considered to be over % Received radiation therapy to more than % of the bone marrow-containing spaces < days prior to first dose of study medication Patients who have received either immunotherapy within =< weeks; chemotherapy within =< weeks; or radiation therapy to > % of marrow-bearing bone within =< weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies Prior radiation therapy to < % of the bone marrow [see bone marrow radiation chart in the study procedure manual (SPM)] allowed if completed within days prior to registration for protocol therapy. Prior radiation to ? % of bone marrow or any radiation therapy within days prior to randomization Radiation therapy to more than % of the bone marrow; whole pelvic radiation is considered to be over % Diagnosis of another primary cancer for which the patient is currently undergoing radiation therapy, chemotherapy, or bone marrow transplant Current systemic chemotherapy or radiation therapy that potentially causes bone marrow suppression that would preclude safe treatment of HSIL Prior radiation therapy is allowed; patients must not have received any radiation within weeks prior to the initiation of study treatment; patients may not have areas of irradiated marrow exceeding % of bone marrow volume Prior treatment with radiation therapy involving greater than or equal to (>=) % of the hematopoietically active bone marrow. The patient has received radiation to ? % of his or her bone marrow within weeks of the first dose of study drug.